IP Library Granted Patent US 10,064,922
Granted Patent B2
US 10,064,922 · App. 14/349,862 · Granted Sep 4, 2018

Compositions and methods for immune tolerance induction

Inventor: Sathy V. Balu-Iyer (Amherst, NY)
Assignee: The Research Foundation for The State University of New York
A61K39/0005A61K9/127A61K38/37A61K38/47A61K47/6911C12Y302/0102A61K2039/577A61K2039/6018
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,064,922
App. No.
14/349,862
Granted
Sep 4, 2018
Kind
B2
Abstract

Methods and compositions to reduce immunogenicity of proteins are disclosed. Compositions comprising therapeutic proteins (such as Factor VIII or any other protein or peptide) complexed with liposomes comprising PS and PC (PS liposomes), or comprising PS, PI and PC and, optionally, cholesterol (PS/PI liposomes) may be used.

Claims (10)

1. A method for inducing in an individual immune tolerance to a therapeutic protein comprising the steps of:

a) administering multiple times to the individual a first composition comprising the protein complexed to liposomes comprising i) phosphatidylserine (PS) and phosphatidylcholine (PC), or ii) phosphatidylserine (PS), phosphatidylinositol (PI), and phosphatidylcholine (PC);

b) after waiting for at least 4 days after the last administration of the first composition administering to the individual a second composition comprising the protein, wherein the second composition is free of liposomes.

2. The method of claim 1 , wherein the liposomes of the first composition comprise PS:PC in a ratio of 10:90 to 50:50 mol %.

3. The method of claim 1 , wherein the liposomes of the first composition comprise PS:PC in a ratio of 30:70 mol %.

4. The method of claim 1 , wherein the liposomes of the first composition comprise PS:PI:PC in a ratio of 30:30:40 mol % and, optionally, further comprise 5-15% cholesterol, wherein the cholesterol amount is a molar percent of the combined PS, PI and PC.

5. The method of claim 1 , wherein the protein is Factor VIII.

6. The method of claim 1 , wherein the second composition is administered after waiting for at least 7 days after the last administration of the first composition.

7. The method of claim 1 , wherein the priming compositions is administered via the subcutaneous route.

8. The method of claim 1 , wherein the development of immune tolerance is detectable by down-regulated expression of co-stimulatory signals on dendritic cells, lowered CD4+ T-cell proliferation and/or induced secretion of TGF-β and IL-10.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2014
From: BALU-IYER, SATHY
To: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Reel/Frame 034461/0626 →
Continuity (3)
Provisional Application 61607195 · Mar 6, 2012
Provisional Application 61543859 · Oct 6, 2011
Related Publication 20150004218A1 · Jan 1, 2015